Dr. Reddy’s Delays Generic Ozempic Supply After Ingredient Issue
2026-07-09 05:11:17
Dr. Reddy’s Laboratories Ltd. will delay commercial production of its generic Ozempic after finding an unspecified issue with the active pharmaceutical ingredient in some batches of semaglutide, according to Bloomberg.
Disclaimer:
1. The information provided does not constitute investment advice. Investors should make independent decisions and bear all risks themselves.
2. The copyright of this content belongs to the original author. The views expressed herein are solely those of the author and do not represent the stance or position of this website.
